ATIS is on the move! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move!

ATIS 0.1000

-47.4%

Apr 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who wrote (1207)	12/9/1997 12:03:00 PM
From: Harry D. Kramer	Read Replies (2) of 2205

That is possible, although not very likely. But I do not want to start an IMNX discussion on this thread. This was just an arbitrary example. A valuation discussion on IMNX would take much longer than the current ATIS discussion. Going back to ATIS, you obviously think that there is an unusually high risk at the commercialization stage for Dermagraft. Why? Apart from all the aspects that have been mentioned in prior posts and which I would consider average risk for a biotech company at this stage (new technology concept, potential competitors like Regranex, etc., etc., .......). Be more specific! Harry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next